MGMT and neoplasm: In the case of gliomas, biomarkers such as isocitrate dehydrogenase (IDH) mutational status and O [6]-methylguanine DNA methyltransferase (MGMT) methylation are standard of care and provide prognostic insight into tumor behavior [20, 21].